Ajjan N, Soulebot J P, Stellmann C, Biron G, Charbonnier C, Triau R, Mérieux C
Dev Biol Stand. 1978;40:89-100.
Many thousands of people in France and abroad have already benefited from preventive rabies vaccination by means of a vaccine obtained from culture on human diploid cells, perfected ten years ago by R. Lang, the Institut Mérieux and the Wistar Institute. In addition to being well tolerated, the serological efficacy of this vaccine is such that 100% of the vaccines observed had a seroconversion after only two injections at an interval of one month. However, a booster dose should be given 6 to 12 months after the first injection, and a further booster 3 to 5 years later or on request in case of known contamination. These boosters, combined with an anti-tetanus booster, induce such high antibody titers--between 10-100 and even 1000 I.U./ml--that it is easy to obtain substantial batches of combined anti-rabies and anti-tetanus immunoglobulin from a small number of volunteers. The complete efficacy of this new vaccine reduces the number of systematic post-vaccinal serologic controls and its innocuity is such that an extended preventive vaccination programme may be carried out, for instance in the case of children living in areas known to be dangerous.
成千上万的法国国内外人士已经受益于通过人二倍体细胞培养获得的狂犬病预防疫苗,该疫苗于十年前由R. 朗、梅里埃研究所和威斯塔研究所研发完善。这种疫苗不仅耐受性良好,其血清学效果也十分显著,100%接受观察的接种者在仅间隔一个月进行两次注射后就出现了血清转化。然而,首次注射后6至12个月应给予加强剂量,3至5年后或在已知感染的情况下应要求再进行一次加强注射。这些加强注射与破伤风抗毒素加强注射相结合,可诱导出高达10 - 100甚至1000国际单位/毫升的抗体滴度,因此很容易从少数志愿者身上获得大量的狂犬病和破伤风联合免疫球蛋白。这种新疫苗的完全有效性减少了接种后系统性血清学检查的次数,而且其无害性使得可以开展扩大的预防接种计划,例如针对生活在已知危险地区的儿童。